Related Experiment Video
Updated: Aug 11, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Antiretroviral therapeutic possibilities for human immunodeficiency virus/acquired immunodeficiency syndrome
1Laboratory of Clinical Pharmacology, Department of Psychiatry, New Clinics, University of Szeged, Medical Faculty, G.P.O. Box 427, H-6701 Szeged, Hungary. balint@nepsy.szote.u-szeged.hu
Abstract:
In human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) illness, the reverse transcriptase and protease (PRT) enzymes of HIV are currently the targets of antiretroviral (ARV) therapy. Nucleoside analogues were the first group of ARV drugs that exerted antiviral activity in patients. More recently, PRT inhibitors have provided new approaches in the treatment of HIV infection and AIDS. Impressive clinical results have been obtained with combination therapies of three ARV drugs, including one PRT inhibitor. It is worth mentioning also that apart from these two main drug groups, there are many new compounds under development, including a vaccine(s) against HIV.
Related Concept Videos
Retrovirus Life Cycles
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Sexually Transmitted Infections
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly

